An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
NCT #
NCT04008797
Condition(s)
Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor
Molecular Target(s)
CBP/beta-catenin
Drug Classification(s)
Small Molecule
Agents(s)
E7386
Phase(s)
I
Mechanism of Action
E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth.
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from E7386
- How the study drug is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.